STAT Plus: Myovant endometriosis drug meets its goal in a second late-stage trial, company says
ADOBE
Myovant has been testing the hormone blocker relugolix as a treatment for endometriosis, uterine fibroids, and advanced prostate cancer.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario